BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao HT, Cai JQ. Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma. World J Gastroenterol 2021; 27(47): 8069-8080 [PMID: 35068855 DOI: 10.3748/wjg.v27.i47.8069] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 An LN, Du L, Wang LL, Chen J, Wang XR, Duan JP. Comprehensive analysis of an autophagy-related prognostic model for predicting survival based on TCGA and ICGC database in hepatocellular carcinoma patients. J Gastrointest Oncol 2022;13:3154-68. [PMID: 36636069 DOI: 10.21037/jgo-22-1130] [Reference Citation Analysis]
2 Chen B, Lei J, Zhao H, Dong J, Zeng Z, Li Y, Yu L, Zhou L, Jia A, Lu Y, Cheng J. Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study. JHC 2022;Volume 9:1171-1185. [DOI: 10.2147/jhc.s387254] [Reference Citation Analysis]
3 Chen K, Luo C, Ge D, Wang K, Luo Q, Li Y, You X, Xiang B, Li L, Ma L, Zhong J. Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma. Front Oncol 2022;12:946693. [DOI: 10.3389/fonc.2022.946693] [Reference Citation Analysis]
4 Bei H, Mai W, Chen W, Li M, Yang Y. Application of systemic treatment in conversion therapy options for liver cancer. Front Oncol 2022;12:966821. [DOI: 10.3389/fonc.2022.966821] [Reference Citation Analysis]
5 Guan R, Yu C, Li S, Mei J, Wei W, Guo R. A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Front Pharmacol 2022;13:998534. [DOI: 10.3389/fphar.2022.998534] [Reference Citation Analysis]
6 Orimo T, Kamiyama T, Kakisaka T, Nagatsu A, Asahi Y, Aiyama T, Kamachi H, Taketomi A. Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas. Ann Surg Oncol. [DOI: 10.1245/s10434-022-12495-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review. Front Immunol 2022;13:913464. [DOI: 10.3389/fimmu.2022.913464] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Lin Q, Chen D, Li K, Fan X, Cai Q, Lin W, Qin C, He T. Case Report: Massive Hepatocellular Carcinoma Complete Surgical Resection After Portal Vein Embolization and Multimodality Therapy. Front Radio 2022;2. [DOI: 10.3389/fradi.2022.858963] [Reference Citation Analysis]